<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725890</url>
  </required_header>
  <id_info>
    <org_study_id>196</org_study_id>
    <nct_id>NCT04725890</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes</brief_title>
  <acronym>REGENT-1</acronym>
  <official_title>Safety and Feasibility of Endoscopic Application of a Novel Therapy for Duodenal Mucosal Regeneration in the Treatment of Type II Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DyaMX Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DyaMX Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to assess the safety and feasibility of the DyaMX device for&#xD;
      endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately&#xD;
      controlled on 1-3 non-insulin glucose-lowering medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who sign the informed consent will be screened for study eligibility. Eligible&#xD;
      participants will be treated with the DyaMX procedure and followed up for 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device- or Procedure-related SAE Rate</measure>
    <time_frame>12 weeks post procedure</time_frame>
    <description>Proportion of participants experiencing one or more device- or procedure-related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>4, 12, 24, 36, 48 weeks</time_frame>
    <description>Mean changes from baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting plasma glucose</measure>
    <time_frame>4, 12, 24, 36, 48 weeks</time_frame>
    <description>Mean changes from baseline in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin resistance</measure>
    <time_frame>4, 12, 24, 36, 48 weeks</time_frame>
    <description>Mean changes from baseline in HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean changes from baseline in ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AST</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean changes from baseline in AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>4, 12, 24, 36, 48 weeks</time_frame>
    <description>Percent changes from baseline in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>4, 12, 24, 36, 48 weeks</time_frame>
    <description>Mean changes from baseline in blood pressure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Procedure success</measure>
    <time_frame>during procedure</time_frame>
    <description>Percentage of participants with successful DMR procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedure time</measure>
    <time_frame>during procedure</time_frame>
    <description>Time between catheter insertion to catheter removal</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible participants will receive the DyaMX procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The DyaMX Device</intervention_name>
    <description>The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Duodenal Mucosal Regeneration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years of age&#xD;
&#xD;
          2. Current diagnosis of T2D&#xD;
&#xD;
          3. History of T2D for less than or equal to 8 years&#xD;
&#xD;
          4. HbA1C of 8.0-11.0%, inclusive&#xD;
&#xD;
          5. BMI 24-40 kg/m2, inclusive&#xD;
&#xD;
          6. On stable non-insulin glucose lowering mediations (1-3 medications) for at least 12&#xD;
             weeks prior to baseline visit&#xD;
&#xD;
          7. Weight stability (defined as a &lt; 5% change in body weight) for at least 12 weeks prior&#xD;
             to the screening visit&#xD;
&#xD;
          8. Agree not to donate blood during participation in the study.&#xD;
&#xD;
          9. Able to comply with study requirements and understand and sign the Informed Consent&#xD;
             Form&#xD;
&#xD;
         10. Women of childbearing potential must be using an acceptable method of contraception&#xD;
             throughout the study&#xD;
&#xD;
         11. Willing and able to perform self-monitoring blood glucose and comply with study visits&#xD;
             and study tasks as required per protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with type 1 diabetes&#xD;
&#xD;
          2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma&#xD;
&#xD;
          3. Probable insulin production failure, defined as overnight fasting C-peptide serum &lt;1&#xD;
             ng/mL (333pmol/l).&#xD;
&#xD;
          4. Previous use of any types of insulin for &gt;1 month (at any time, except for treatment&#xD;
             of gestational diabetes) in last 2 years.&#xD;
&#xD;
          5. Current use of insulin&#xD;
&#xD;
          6. Hypoglycemia unawareness&#xD;
&#xD;
          7. History of â‰¥1 severe hypoglycemia (defined by needing for third-party assistance),&#xD;
             unless a clear correctable precipitating factor can be identified, in past 6 months&#xD;
             from the screening visit&#xD;
&#xD;
          8. Known autoimmune disease, as evidenced by a positive anti-glutamic acid decarboxylase&#xD;
             (GAD) test, including but not limited to celiac disease, or pre-existing symptoms of&#xD;
             systemic lupus erythematosus, scleroderma or other autoimmune connective tissue&#xD;
             disorder.&#xD;
&#xD;
          9. Previous GI surgery that has changed GI anatomy or could limit treatment of the&#xD;
             duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar&#xD;
             procedures or conditions.&#xD;
&#xD;
         10. Known history of a structural or functional disorder of the upper GI tract that may&#xD;
             impede passage of the device through the upper GI tract or increase risk of tissue&#xD;
             damage during an endoscopic procedure, including esophagitis, stricture/stenosis,&#xD;
             varices, diverticula, or other disorder of the esophagus, stomach and duodenum.&#xD;
&#xD;
         11. Active H. pylori infection (Participants with active H. pylori may continue with the&#xD;
             screening process if they are treated with an appropriate antibiotic regimen)&#xD;
&#xD;
         12. History of, or gastrointestinal symptoms suggestive of gastroparesis.&#xD;
&#xD;
         13. Acute gastrointestinal illness in the previous 7 days&#xD;
&#xD;
         14. Known history irritable bowel syndrome, radiation enteritis or other inflammatory&#xD;
             bowel disease, such as Crohn's disease and Celiac disease&#xD;
&#xD;
         15. History of chronic or acute pancreatitis.&#xD;
&#xD;
         16. Known active hepatitis or active liver disease other than NASH/NAFLD.&#xD;
&#xD;
         17. Alcoholic liver disease, as indicated by ANI &gt;0&#xD;
&#xD;
         18. Current use of anticoagulation therapy (such as warfarin) that cannot be discontinued&#xD;
             for 7 days before and 14 days after the procedure.&#xD;
&#xD;
         19. Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be&#xD;
             discontinued for 14 days before and 14 days after the procedure.&#xD;
&#xD;
         20. Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during treatment&#xD;
             through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin is&#xD;
             allowed.&#xD;
&#xD;
         21. Use of systemic glucocorticoids (excluding topical or ophthalmic application or&#xD;
             inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline&#xD;
             visit.&#xD;
&#xD;
         22. Use of drugs known to affect GI motility (e.g. Metoclopramide)&#xD;
&#xD;
         23. Use of weight loss medications such as Phentermine, Meridia, Xenical, or&#xD;
             over-the-counter weight loss medications (prescription medication)&#xD;
&#xD;
         24. Persistent anemia, defined as hemoglobin &lt;10 g/dL.&#xD;
&#xD;
         25. Known history of blood donation or transfusion within 3 months prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
         26. Known history of cardiac arrhythmia&#xD;
&#xD;
         27. Significant cardiovascular disease, including known history of valvular disease, or&#xD;
             myocardial infarction, heart failure, transient ischemic attack, or stroke within 6&#xD;
             months prior to the Screening Visit.&#xD;
&#xD;
         28. Estimated glomerular filtration rate (eGFR) â‰¤ 30 ml/min/1.73m2.&#xD;
&#xD;
         29. Known immunocompromised status, including but not limited to individuals who have&#xD;
             undergone organ transplantation, chemotherapy, or radiotherapy within the past 12&#xD;
             months, who have clinically-significant leukopenia, who are positive for the human&#xD;
             immunodeficiency virus (HIV) or whose immune status makes the participant a poor&#xD;
             candidate for clinical trial participation in the opinion of the investigator.&#xD;
&#xD;
         30. With any implanted electronic devices or duodenal metallic implants&#xD;
&#xD;
         31. Not a candidate for upper GI endoscopy or general anesthesia.&#xD;
&#xD;
         32. Active illicit substance abuse or alcoholism (&gt; 2 drinks/day regularly).&#xD;
&#xD;
         33. Active malignancy within the last 5 years (excluding non-melanoma skin cancers)&#xD;
&#xD;
         34. Women breast feeding&#xD;
&#xD;
         35. Participating in another ongoing clinical trial of an investigational drug or device.&#xD;
&#xD;
         36. Any other mental or physical condition which, in the opinion of the study&#xD;
             investigator, makes the participant a poor candidate for clinical trial participation.&#xD;
&#xD;
         37. Critically ill or has a life expectancy &lt;3 years&#xD;
&#xD;
             Additional exclusion criteria to be confirmed during the screening process:&#xD;
&#xD;
         38. HbA1c &lt; 8.0% or &gt; 11% at baseline visit&#xD;
&#xD;
         39. Any severe hypoglycemic event since the screening visit&#xD;
&#xD;
         40. Glucose level &lt;54 mg/dl (3.0 mmol/l) in more than 1% of time by CGM since the&#xD;
             screening visit&#xD;
&#xD;
         41. Uncontrolled hyperglycemia with a glucose level &gt;270 mg/dl (&gt;15 mmol/L) after an&#xD;
             overnight fast or &gt;360 mg/dl (&gt;20 mmol/l) in a randomly performed measurement that is&#xD;
             confirmed by a second measurement (not on the same day) since screening visit&#xD;
&#xD;
         42. Mean of 3 separate blood pressure measurements &gt;180 mmHg (systolic) or &gt;100 mmHg&#xD;
             (diastolic)&#xD;
&#xD;
         43. Women of child-bearing potential with a positive urine pregnancy test at baseline&#xD;
             visit&#xD;
&#xD;
         44. Grade III or greater esophagitis on endoscopy&#xD;
&#xD;
         45. Abnormalities of the GI tract preventing endoscopic access to the duodenum&#xD;
&#xD;
         46. Anatomic abnormalities in the duodenum that would preclude the completion of the&#xD;
             treatment procedure, including tortuous anatomy&#xD;
&#xD;
         47. Endoscopic observation of upper gastrointestinal abnormality such as ulcers, polyps,&#xD;
             varices, strictures, congenital or intestinal telangiectasia&#xD;
&#xD;
         48. Any other anatomical or endoscopic abnormalities/characteristics that, in the opinion&#xD;
             of the investigator, would preclude safe use of the investigational device or&#xD;
             procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Sartoretto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The BMI Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lian Cunningham</last_name>
    <phone>+1 763 251 6825</phone>
    <email>lcunningham@dyamx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The BMI Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2028</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Manolios</last_name>
      <phone>+61 2 8596 3233</phone>
      <email>regent@bmiclinic.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

